BERLIN, Feb 7 (Reuters) - Swiss pharmaceutical company Roche said on Saturday its experimental multiple sclerosis drug ...
Biogen swung to a loss as results were hurt by a double-digit decline in revenue from its core multiple sclerosis treatments.
Biogen swung to a loss as results were hurt by a double-digit decline in revenue from its core multiple sclerosis treatments.
The court agreed on a block for early generics of a widely prescribed MS treatment, finding even though a psoriasis ...
Cerebrospinal fluid (CSF)-based molecular tests can reliably distinguish multiple sclerosis (MS) from other neurological ...
Roche has shared the numbers behind its phase 3 win in primary progressive multiple sclerosis (PPMS), linking its BTK ...
New clinical trial data suggest vidofludimus calcium can target key mechanisms underlying progressive multiple sclerosis.
Tolebrutinib failed to lower disability progression risk in primary progressive MS in a Phase 3 trial, with data shown at ...
Learn how early diagnosis and modern therapies can prevent Multiple Sclerosis from leading to long-term disability.
Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary endpoint of ...
A new study reveals how Epstein-Barr virus may provoke immune cells to attack the brain, offering fresh hope for treating ...
Chennai: At 25, Bhanupriya was just another TNPSC aspirant from Madurai, preparing for her exams. One day, she lost partial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results